MIAMI--(BUSINESS WIRE)--Stimwave Technologies Incorporated, a privately held, commercial stage medical device company, today announced the appointment of Dr. Gabor Racz as the chair of the Stimwave medical advisory board. Honored with numerous lifetime achievement awards throughout the industry, Dr. Racz is considered by many to be the “father of interventional pain medicine.” Dr. Racz will join an all-star cast of clinicians specializing in pain management, neuromodulation, and minimally invasive spine surgery on the Stimwave Medical Advisory Board.
“We are extremely pleased to welcome Dr. Gabor Racz to our outstanding team of medical advisors,” said Laura Tyler Perryman, chairman and CEO of Stimwave Technologies. “Dr. Racz is a renowned leader in the field of pain medicine, and we look forward to benefiting from his guidance and expertise as we bring Stimwave’s revolutionary Wireless Pain Relief™ technology to the treatment of chronic pain in the U.S. and around the world.”
Dr. Racz has been honored with a multitude of lifetime achievement awards from societies throughout the world in recognition of contributions that span more than five decades. Dr. Racz is one of the founders and past presidents of the World Institute of Pain (WIP), as well as chairman emeritus and a lifetime member of the executive board.
Dr. Racz was also instrumental in the development of the American Society of Interventional Pain Physicians (ASIPP), a society of over 4,500 members specializing in pain medicine. In honor of Dr. Racz, the annual keynote speech of the society is called the Raj and Racz Award. He is currently chairman emeritus at the Department of Anesthesiology at Texas Tech University Health Science Center in Lubbock, Texas and an acknowledged Grover E. Murray Professor. Frequently credited as the “father of interventional pain medicine,” Dr. Racz was the first to introduce the concept of using needle/catheter-based procedures to replace drug and other therapies for people suffering from chronic pain.
“Stimwave’s Wireless Pain Relief™ represents the field’s cutting-edge and serves as an affirmation of the idea that needle-based procedures provide a viable, minimally invasive alternative with maximum impact,” said Dr. Racz. “I am honored to lead Stimwave’s medical advisory board and to contribute to the development of this revolutionary chronic pain treatment.”
Dr. Racz joins a prestigious roster of fellow physicians on the Stimwave board, including:
- David Kloth, MD, FIPP: Dr. Kloth is the founder and medical director of Connecticut Pain Care and is the current president of the North American Neuromodulation Society (NANS) and long standing board member, and author of Pain Wise (2011). Dr. Kloth is also a past president of the American Society of Interventional Pain Physicians (ASIPP) and currently serves on its Board of Directors.
- Dr. Ralph Rashbaum: Dr. Rashbaum is an orthopedic surgeon who has performed more than 2,000 procedures during his 35-plus years of experience in spinal cord stimulation. Dr. Rashbaum is also the co-founder of the Texas Back Institute.
- Dr. Anthony Yeung: Dr. Yeung is the inventor of minimally invasive spine surgery and transformational percutaneous techniques called YESS. Dr. Yeung is a board certified orthopedic spine surgeon at the Desert Institute for Spine Care (DISC) in Phoenix, Arizona.
- Dr. Mark Coleman: Dr. Coleman is a pain specialist with more than 20 years of spinal cord stimulation experience. He is one of the principals of National Pain and Spine Centers, one of the largest pain management medical groups in the country.
Please visit www.stimwave.com for more information on the availability of Stimwave.
Stimwave Technologies Incorporated is a privately held medical device company engaged in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management.